Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly

Label Warning Will Be Key

Executive Summary

AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.

You may also be interested in...



Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021

HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.

Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies

A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel